Michael Davidson/LinkedIn
Nov 23, 2025, 14:48
Michael Davidson: Why LDL Alone Isn’t Enough for CV Risk Reduction
Michael Davidson, CEO of NewAmsterdam Pharma, posted on LinkedIn:
”Today’s standard lipid-lowering therapies focus almost exclusively on LDL-C reduction. Yet across large-scale studies, only 20–35% of patients taking them are meeting their risk-based LDL-C goals, highlighting the need for additional therapies.
Additionally, to maximize cardiovascular risk reduction, we need to address additional factors like lipoprotein(a), small LDL particles, and ApoB.
Learn how we can broaden the approach to reducing cardiovascular risk.”
Read more here.
Stay updated wth Hemostasis Today.
-
Sep 10, 2026, 05:12Douglas S. Campbell: Great to See a Strong Japanese Presence in 2026 Lasker Awards
-
Sep 10, 2026, 05:11Jan Hartmann: New Transformative Treatment for Hemophilia A
-
Sep 10, 2026, 05:09Shelby Bradford: Award-Winning Science Incoming
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH